Bailard Inc. boosted its stake in shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) by 57.4% in the third quarter, HoldingsChannel.com reports. The firm owned 74,000 shares of the company’s stock after purchasing an additional 27,000 shares during the quarter. Bailard Inc.’s holdings in DBV TECHNOLOGIE/S were worth $1,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in DBV TECHNOLOGIE/S by 4.7% during the 2nd quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares during the period. Exane Asset Management boosted its position in DBV TECHNOLOGIE/S by 17.9% during the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock worth $964,000 after acquiring an additional 7,600 shares during the period. First Midwest Bank Trust Division boosted its position in DBV TECHNOLOGIE/S by 19.3% during the 3rd quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock worth $3,669,000 after acquiring an additional 26,372 shares during the period. Boxer Capital LLC boosted its position in DBV TECHNOLOGIE/S by 4.4% during the 2nd quarter. Boxer Capital LLC now owns 1,065,000 shares of the company’s stock worth $20,544,000 after acquiring an additional 45,000 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in DBV TECHNOLOGIE/S during the 2nd quarter worth $285,000. Institutional investors and hedge funds own 45.43% of the company’s stock.
Shares of DBVT stock opened at $14.53 on Friday. DBV TECHNOLOGIE/S has a 1 year low of $13.94 and a 1 year high of $26.98. The firm has a market cap of $831.01 million, a price-to-earnings ratio of -4.28 and a beta of 1.18.
ILLEGAL ACTIVITY WARNING: “Bailard Inc. Has $1.66 Million Position in DBV TECHNOLOGIE/S (DBVT)” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.wkrb13.com/2018/12/07/bailard-inc-has-1-66-million-position-in-dbv-technologie-s-dbvt.html.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV TECHNOLOGIE/S (NASDAQ:DBVT).
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.